AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05462925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy.
Description: Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
Study NCT05180734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001/Placebo
Description: JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Study NCT05180734 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Description: JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Study NCT05996003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1
Study NCT06055920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowTriever System
Description: Mechanical Thrombectomy for pulmonary embolism
Study NCT06055920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Agents
Description: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot.
Study NCT04320342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study NCT04320342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study NCT04320342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Bromide
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
Study NCT04320342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study NCT04320342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study NCT05195151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taking capsule containing probiotics or placebo
Description: The probiotics capsule containing two strains of probiotics.
Study NCT05195151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taking capsule containing probiotics or placebo
Description: The probiotics capsule containing two strains of probiotics.
Study NCT06088810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoMPoSER intervention group
Description: Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
Study NCT06088810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
Study NCT05796739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive stress test
Description: Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
Study NCT05796739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment without further testing
Description: Optimal medical treatment for primary prevention.
Study NCT05481879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNE-101
Description: Administered by IV infusion
Study NCT05481879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion
Study NCT05481879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by IV infusion
Study NCT05904119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Oral administration of Lomustine
Study NCT05904119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Oral administration of Lomustine
Study NCT05904119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reirradiation
Description: Given at least 6 months after the end of prior radiotherapy
Study NCT05084196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 5 mg capsule by mouth at bedtime
Study NCT05084196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsule by mouth at bedtime
Study NCT06635018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting conditions
Description: The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.
Study NCT06635018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement artifacts
Description: The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.
Study NCT06635018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulation constriction
Description: The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
Study NCT06636149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit of maternal position changes during labor
Description: The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5
Study NCT06181656 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumonia vaccine
Description: Given by SC
Study NCT05342064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-centered TB preventive therapy
Description: The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
Study NCT05342064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TB preventive therapy adherence support
Description: As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
Study NCT06106828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered by SC injection.
Study NCT06106828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection
Study NCT05634369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM/DOX + TGFBi expanded NK cells
Description: 8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~* Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~* Tumor response assessed after Cycles 2, 4, 6, and 8~  1. Gemcitabine 675mg/m2/dose IV on Days 1 and 8~ 2. Docetaxel 75mg/m2/dose IV on Day 8~ 3. Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~ 4. Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~ 5. NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)
Study NCT06357013 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral Suprainguinal fascia iliaca compartment block
Description: Suprainguinal fascia iliaca compartment block (S-FICB) is one of the commonly used regional analgesia techniques for postoperative analgesia in lower extremity surgeries.
Study NCT06357013 — intervention group
Intervention type: PROCEDURE
Intervention: Local infiltration analgesia
Description: Local infiltration analgesia is applied to the posterior part of the knee, including the periosteum, ligaments, muscle and/or skin area before closing the surgical field.
Study NCT06471361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
Study NCT05839080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gardens to Bellis
Description: In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.
Study NCT05839080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Pupils are not receiving any intervention
Study NCT04802733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSK-DA01
Description: MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
Study NCT04802733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSK-DA01 Cell Delivery Device
Description: A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
Study NCT04902469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleasant Odor
Description: Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
Study NCT04902469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Odor Blank
Description: Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
Study NCT05834504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short distributed training (1-2 days)
Description: The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved.
Study NCT05525533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harnessing prosocial and social image motivations for behavior change
Description: The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
Study NCT04973254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAB-RPV LA
Description: Monthly administration of injectable HIV medication
Study NCT04973254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAB-RPV LA
Description: Monthly administration of injectable HIV medication
Study NCT04973254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment within an HIV clinic
Description: Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
Study NCT05285683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 0.5 mg/kg
Study NCT05285683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa
Description: 25 mg/100 mg
Study NCT05285683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral pill
Study NCT06528587 — intervention group
Intervention type: PROCEDURE
Intervention: narrow diameter implant
Description: Rehabilitation of single edentulism in the anterior region with narrow diameter implants and computer guided surgery.
Study NCT05118282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined coping skills + asthma management
Description: This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
Study NCT05118282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Management (AM)
Description: This arm includes a curriculum teaching standard asthma management skills.
Study NCT05992545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application 'DangDang Care' under usual care
Description: The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy.~The intervention group receives the mobile application with usual care.
Study NCT05921084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIND diet intervention
Description: The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
Study NCT05921084 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General dietary advice
Description: General dietary advice
Study NCT05122585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MagSeed and MagTrace in breast cancer patiënts
Description: Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
Study NCT06132568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITALYST System
Description: The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
Study NCT06439550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 300mg, q3w
Study NCT06439550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First dose 8mg/kg, maintenance 6mg/kg, q3w
Study NCT06439550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Tegafur
Description: oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
Study NCT05741385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine
Study NCT05141578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luci Coach Assisted Intervention
Description: The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24.
Study NCT05686278 — intervention group
Intervention type: DEVICE
Intervention: Bipolar i and cemented stem (Océane+ or Meije)
Description: Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
Study NCT06389279 — intervention group
Intervention type: OTHER
Intervention: PENG block group
Description: Ultrasound-guided PENG block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
Study NCT06389279 — intervention group
Intervention type: OTHER
Intervention: FIC block group
Description: Ultrasound-guided FIC block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
Study NCT06389279 — intervention group
Intervention type: OTHER
Intervention: Femoral block group
Description: Ultrasound-guided femoral block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
Study NCT06389279 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: No intervention
Study NCT05741385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Description: Warfarin sodium
Study NCT05741385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole
Study NCT05741385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol
Study NCT05741385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study NCT04848506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten (5 - 20 mg)
Description: Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
Study NCT05363397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBO-309
Description: TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
Study NCT06182774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Dose determined at enrollment
Study NCT06182774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Dose determined at enrollment
Study NCT06182774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose determined at enrollment
Study NCT06182774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dose determined at enrollment
Study NCT06182774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose determined at enrollment
Study NCT04446481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback will be tested in both groups of Vets
Study NCT04446481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Neurofeedback will be tested in both groups of Vets
Study NCT06163833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell low dosage-80*10^6 cells
Description: MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL.
Study NCT06163833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell low dosage-160*10^6 cells
Description: MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL.